Heart Health

This news channel includes content on cardiovascular disease prevention, cardiac risk stratification, diagnosis, screening programs, and management of major risk factors that include diabetes, hypertension, diet, life style, cholesterol, obesity, ethnicity and socio-economic disparities.

Dexcom issues new recall for CGM apps due to safety risk—users urged to update immediately
The FDA has categorized this as a Class I recall. If patients update their phone or watch apps as needed, they can continue to use these devices like normal.
Plant-based diets linked to lower risks of death, heart disease, stroke and diabetes
Diets that prioritize plant-based foods are associated with several health benefits, according to a new study of more than 3.4 million adults. Such diets also show potential to reduce greenhouse gas emissions.
Health systems use AI to target patients who may have elevated Lp(a) levels
"We can start helping people right now, and it would be meaningful if we can raise more awareness to reduce the burden of CVD," explained Katherine Wilemon, founder and CEO of the Family Heart Foundation.
Oral GLP-1 drug linked to weight loss in patients with and without diabetes—is FDA approval next?
Eli Lilly and Company is back with even more positive data on orforglipron, its oral GLP-1 receptor agonist. The company says it is "moving with urgency" toward gaining key regulatory approvals and getting the drug in the hands of patients.
Cardiology group thanks Taylor Swift for spreading word about nuclear stress testing
When Taylor Swift speaks, the world listens. And when she recently appeared on a podcast for the very first time, she shared the story of how a nuclear stress test saved her father's life.

Updated: Dexcom recalls more than 700K CGM receivers over safety issues—dozens of adverse events reported

There is an increased risk that these devices will not provide audible alerts for low or high blood glucose levels. The FDA has ruled that this is a Class I recall, highlighting the safety risks associated with missed alerts.

Janet Wei, MD, Erika J. Glazer Chair in Women’s Cardiovascular Research, Education and Innovation at the Smidt Heart Institute at Cedars-Sinai Hospital, explains the key differences between men and women in cardiovascular disease presentations and disease progression. She said heart disease its the number one cause of death in women and the guidelines cannot be a one size fits all document lumping men and women together, they really need to separate out specific details for women.

Cardiology societies should develop separate guidelines for treating female heart patients

Janet Wei, MD, examined the key differences between men and women when it comes to cardiovascular disease. These differences, she said, highlight why female patients need their very own treatment guidelines.

Eli Lilly to acquire gene-editing specialists focused on CVD for up to $1.3B

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

Medtronic’s diabetes spin-off gets a name, kicking off ‘new and exciting chapter’

The new name will be familiar to anyone who knows the history of Medtronic's diabetes business.

Meditation linked to ‘real, lasting benefits’ for high-risk heart patients

A popular meditation technique may help high-risk patients protect their hearts for up to 10 years, according to a new randomized controlled trial published in Frontiers in Medicine.

UTA's lower body negative-pressure pants for MRI stress tests

Inspired by astronauts, researchers use high-tech pants to uncover heart issues on MRI

New first-in-human data highlight the potential of pants designed to improve the quality of MRI-based cardiac stress tests.

cardiologist doctor physician patient black diverse hypertension

FDA approves 3-in-1 polypill for hypertension

Widaplik, the new polypill from George Medicines, includes telmisartan, amlodipine and indapamide. The FDA's decision comes after positive data were published in both JACC and The Lancet.

Paul Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at Harvard Medical School, and Director of the Center for Cardiovascular Disease Prevention, at Brigham and Women’s Hospital, explains the role of high sensitivity C-reactive protein (hs-CRP) in detecting coronary inflammation and the opportunities to improve outcomes with targeted therapies.

Inflammation playing a much bigger role in heart disease evaluations

From new drug therapies and imaging technologies to updated prevention strategies, nearly every aspect of cardiovascular care is starting to embrace the value of coronary inflammation evaluations. Paul Ridker, MD, MPH, discussed the trend in a new interview.

Heart Health

Dexcom issues new recall for CGM apps due to safety risk—users urged to update immediately

Plant-based diets linked to lower risks of death, heart disease, stroke and diabetes

Health systems use AI to target patients who may have elevated Lp(a) levels

Oral GLP-1 drug linked to weight loss in patients with and without diabetes—is FDA approval next?

Cardiology group thanks Taylor Swift for spreading word about nuclear stress testing